(Q51798516)

English

Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.

scientific article published in January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George J Kontoghiorghes

4

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

author name string

Annita Kolnagou

1

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

Charalambos Economides

2

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

Eleni Eracleous

3

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

30

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

2

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

219-227

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

describes a project that uses

magnetic resonance imaging

1 reference

based on heuristic

inferred from title

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Ultrastructural pathology of the heart in patients with beta-thalassaemia major.

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Hepatic iron concentration and total body iron stores in thalassemia major.

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Effects of ICL670 (deferasirox) on cardiac iron concentrations

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642542

21 January 2018

Identifiers

10.1080/03630260600642542

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/16798647

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51798516&oldid=1877321729"